Bayer says Xarelto isn't losing U.S. market share to Eliquis

April 30, 2015 1:15 PM

13 0

FRANKFURT, April 30 (Reuters) - Bayer brushed off concern that its stroke prevention pill Xarelto may be losing market share to rival Bristol-Myers Squibb's Eliquis in the United States.

The German drugmaker told analysts during a conference call on Thursday that Eliquis was taking business from warfarin and other drugs, but not from Xarelto.

Also read: Many condominiums for sale, rent at Chicago's Trump Tower

Read more

To category page